Novo Nordisk Q3 Sales Beat Forecasts In New CEO's Maiden Quarter

Reuters

Nov 05

COPENHAGEN, Nov 5 (Reuters) - Wegovy-maker Novo Nordisk NOVOb.CO on Wednesday reported third-quarter sales growth of 15%, beating forecasts in a boost to the Danish drugmaker's new CEO amid a deep restructuring drive to claw back lost ground in a fierce obesity drug market battle.

Novo Nordisk shares dropped 3% in overnight trading.

The Danish company said it lowered its full-year profit forecast, while also lowering the top end of its full-year sales forecast range.

The rise in sales in local currency terms, which has slowed sharply in the last year as competition has risen from rival Eli Lilly LLY.N and copycat treatments, compared with 11.4% growth expected by analysts in a company-compiled consensus.

Novo shot to become Europe's most valuable firm on the back of rapid sales growth of its blockbuster obesity drug Wegovy, but has seen sales growth slow, sparking a management overhaul and dragging down its share price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2581717040"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581717040\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581717040?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 14:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581717040","market":"nz","top_or_hot":-1,"title":"Novo Nordisk Q3 Sales Beat Forecasts In New CEO's Maiden Quarter","media":"Reuters","content":"<html><head></head><body><p>COPENHAGEN, Nov 5 (Reuters) - Wegovy-maker Novo Nordisk NOVOb.CO on Wednesday reported third-quarter sales growth of 15%, beating forecasts in a boost to the Danish drugmaker&#39;s new CEO amid a deep restructuring drive to claw back lost ground in a fierce obesity drug market battle.</p><p>Novo Nordisk shares dropped 3% in overnight trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/5c326b1b5b2cf3f630970eb757c4683d\" tg-width=\"837\" tg-height=\"831\"/></p><p>The Danish company said it lowered its full-year profit forecast, while also lowering the top end of its full-year sales forecast range.</p><p>The rise in sales in local currency terms, which has slowed sharply in the last year as competition has risen from rival Eli Lilly LLY.N and copycat treatments, compared with 11.4% growth expected by analysts in a company-compiled consensus.</p><p>Novo shot to become Europe&#39;s most valuable firm on the back of rapid sales growth of its blockbuster obesity drug Wegovy, but has seen sales growth slow, sparking a management overhaul and dragging down its share price.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Q3 Sales Beat Forecasts In New CEO's Maiden Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Q3 Sales Beat Forecasts In New CEO's Maiden Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 14:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>COPENHAGEN, Nov 5 (Reuters) - Wegovy-maker Novo Nordisk NOVOb.CO on Wednesday reported third-quarter sales growth of 15%, beating forecasts in a boost to the Danish drugmaker&#39;s new CEO amid a deep restructuring drive to claw back lost ground in a fierce obesity drug market battle.</p><p>Novo Nordisk shares dropped 3% in overnight trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/5c326b1b5b2cf3f630970eb757c4683d\" tg-width=\"837\" tg-height=\"831\"/></p><p>The Danish company said it lowered its full-year profit forecast, while also lowering the top end of its full-year sales forecast range.</p><p>The rise in sales in local currency terms, which has slowed sharply in the last year as competition has risen from rival Eli Lilly LLY.N and copycat treatments, compared with 11.4% growth expected by analysts in a company-compiled consensus.</p><p>Novo shot to become Europe&#39;s most valuable firm on the back of rapid sales growth of its blockbuster obesity drug Wegovy, but has seen sales growth slow, sparking a management overhaul and dragging down its share price.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BLSP4239.USD","symbol_name":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL6N3WH0CX:1","article_id":"2581717040","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581717040","pubTimestamp":1762325156,"columns":[{"name":"Executive Changes","id":29,"label_key":"executive"},{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Novo Nordisk Q3 sales beat forecasts in new CEO's maiden quarterCOPENHAGEN, Nov 5 (Reuters) - Wegovy-maker Novo Nordisk NOVOb.CO on Wednesday reported third-quarter sales growth of 15%, beating foreca","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","SG9999002232.USD":"Allianz Global High Payout USD","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","NVO":"诺和诺德","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC"},"translate_title":"诺和诺德新任首席执行官首个季度第三季度销售额超出预期","themeId":"8f2595b4216da5a34ef7803394ef1f59","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":0.9},"content_text":"COPENHAGEN, Nov 5 (Reuters) - Wegovy-maker Novo Nordisk NOVOb.CO on Wednesday reported third-quarter sales growth of 15%, beating forecasts in a boost to the Danish drugmaker's new CEO amid a deep restructuring drive to claw back lost ground in a fierce obesity drug market battle.Novo Nordisk shares dropped 3% in overnight trading.The Danish company said it lowered its full-year profit forecast, while also lowering the top end of its full-year sales forecast range.The rise in sales in local currency terms, which has slowed sharply in the last year as competition has risen from rival Eli Lilly LLY.N and copycat treatments, compared with 11.4% growth expected by analysts in a company-compiled consensus.Novo shot to become Europe's most valuable firm on the back of rapid sales growth of its blockbuster obesity drug Wegovy, but has seen sales growth slow, sparking a management overhaul and dragging down its share price.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}